Compare BYD & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYD | BLLN |
|---|---|---|
| Founded | 1973 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Hotels/Resorts | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.8B |
| IPO Year | 1996 | N/A |
| Metric | BYD | BLLN |
|---|---|---|
| Price | $84.70 | $147.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $90.82 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 973.7K | 596.3K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 264.46 | N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $2,626,730,000.00 | N/A |
| Revenue This Year | $1.71 | $46.29 |
| Revenue Next Year | $2.74 | $30.14 |
| P/E Ratio | $27.67 | ★ N/A |
| Revenue Growth | ★ 9.41 | N/A |
| 52 Week Low | $76.33 | $61.96 |
| 52 Week High | $91.41 | $144.28 |
| Indicator | BYD | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 72.52 |
| Support Level | $83.37 | $79.07 |
| Resistance Level | $85.56 | N/A |
| Average True Range (ATR) | 2.39 | 7.90 |
| MACD | -0.40 | 0.82 |
| Stochastic Oscillator | 23.05 | 96.62 |
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. The Midwest and South hold the key number of entertainment properties and generate the majority of the company's revenue.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.